有机化学人才网 | 最新人才 | 最新职位 | 技术交易 | 药物合成 |
   
全站搜索: |
  您当前位置:网站首页 >> 药物合成路线图解
 

药物详细合成路线

Name Perprazole;(-)-Omeprazole magnesium;(S)-Omeprazole magnesium;Esomeprazole magnesium;H-199/18;Nexium
Chemical Name 5-Methoxy-2-[(S)-(4-methoxy-3,5-dimethyl-2-pyridinylmethyl)sulfinyl]-1H-benzimidazole magnesium salt
CAS 161973-10-0
Related CAS 161796-85-6 (Ca salt), 202742-32-3 (deleted CAS), 217087-10-0 (dihydrate), 119141-88-7 (free acid),
Formula C34H36MgN6O6S2
Structure
Formula Weight 713.14262
Stage 上市-2000
Company AstraZeneca (Originator)
Activity/Mechanism Antiulcer Drugs, Esophageal Diseases, Treatment of, Gastroesophageal Reflux Disease, Agents for, GASTROINTESTINAL DRUGS, H+/K+-ATPase Inhibitors
Syn. Route 2
Route 1
esomeprazole can be obtained by several related ways:1) the naoh-mediated condensation of 2-(chloromethyl)-4-methoxy-3,5-dimethylpyridine (ii), obtained by reaction of the hydroxymethylpyridine (i) with socl2, with 5-methoxy-1h-benzimidazole-2-thiol (v), obtained by cyclization of 4-methoxy-o-phenylenediamine (iii) with potassium ethylxanthate (iv), gives 5-methoxy-2-(4-methoxy-3,5-dimethylpyridin-2-ylmethylsulfanyl)-1h-benzimidazole (vi), which is oxidized with m-chloroperbenzoic acid, yielding racemic omeprazole (vii). the optical resolution of (vii) can be performed by chiral chromatography using several different chiral stationary phases, or by stereoselective bioreduction of the undesired (+)-enantiomer with a purified preparation of dmso reductase from rhodobacter capsulatus dsm 938 that, after reversed phase hplc separation of the reduced sulfanyl derivative (vi), affords an enantiomerically enriched (15:85) mixture of the (+)- and (-)-enantiomers. finally, this mixture is submitted to chiral hplc separation or fractional crystallization in either acetonitrile, 2-butanone or acetone. (scheme 27259801a)2) the asymmetric oxidation of the pro-chiral sulfide (vi) carried out by biooxidation with various microorganisms; among them, the best results (>99% e.e.) were obtained with penicillium frequentans bpfc 386, penicillium frequentans bpfc 585, and brevibacterium praffinoliticum atcc 21195. (scheme 27259801a)3) the asymmetric oxidation of the pro-chiral intermediate (vi) performed with titanium(iv) isopropoxide and cumene hydroperoxide in the presence of (-)-diethyl d-tartrate and diea in toluene.esomeprazole magnesium can be obtained by three different ways: i) by reaction of esomeprazole with magnesium sulfate heptahydrate in aqueous ammonia; ii) by reaction of esomeprazole with magnesium methoxide in methanol or iii) by reaction of esomeprazole sodium, obtained by treatment of esomeprazole with naoh in 2-butanone, with hydrated magnesium chloride in water.
List of intermediates No.
l-threonine; (2r,3s)-2-amino-3-hydroxybutyric acid (ii)
2,2,2-trifluoro-n-[(2s,3r,4s,6r)-3-iodo-6-methoxy-2-methyltetrahydro-2h-pyran-4-yl]acetamide (i)
1,1-dimethoxycyclohexane; 1-methoxycyclohexyl methyl ether (iii)
(2r,3r)-2-[(1s)-2-iodo-1-methyl-2-propenyl]-3-methyl-1,5-dioxaspiro[5.5]undecane (iv)
(2r)-1-[[tert-butyl(dimethyl)silyl]oxy]-3-(1,3-dithian-2-yl)-2-propanol (v)
(2r)-2-(1,3-dithian-2-ylmethyl)oxirane (vi)
(2s)-1-(1,3-dithian-2-yl)-4-penten-2-ol (vii)
(1s)-1-(1,3-dithian-2-ylmethyl)-3-butenyl methyl ether; 2-[(2s)-2-methoxy-4-pentenyl]-1,3-dithiane (xiii)
Reference 1:
    isaksson, r.; pettersson, c.; erlandsson, p.; marle, i.; pettersson, g.; separation of enantiomers using cellulase (cbh i) silica as a chiral stationary phase. j chromatogr 1991, 586, 2, 233.
Reference 2:
    hakusui, h.; yamazaki, h.; tanaka, m.; direct hplc separation of enantiomers of pantoprazole and other benzimidazole sulfoxides using cellulose-based chiral stationary phases in reversed-phase mode. chirality 1995, 7, 8, 612.
Reference 3:
    isaksson, r.; lorentzon, p.; lindberg, p.; erlandsson, p.; resolution of the enantiomers of omeprazole and some of its analogues by liquid chromatography on a trisphenylcarbamoylcellulose-based stationary phase. the effect of the enantiomers of omeprazole on gastric glands. j chromatogr 1990, 532, 305.
Reference 4:
    balmer, k.; persson, b.-a.; lagerstrom, p.-o.; stereoselective effects in the separation of enantiomers of omeprazole and other substituted benzimidazoles on different chiral stationary phases. j chromatogr 1994, 660, 1-2, 269.
Reference 5:
    casta?er, r.m.; casta?er, j.; graul, a.; esomeprazole magnesium. drugs fut 1999, 24, 11, 1178.
Reference 6:
    steiner, u.; lindner, w.; uray, g.; (s,s)-diphenylethylethanediamine derivatives as chiral selectors. ii. gasparrini-type bound chiral stationary phase with high enantioselectivity for naphthylamides. j chromatogr 1991, 553, 1-2, 373.
Reference 7:
    isaksson, r.; pettersson, g.; marle, i.; jonsson, s.; pettersson, c.; chiral stationary phases based on intact and fragmented cellobiohydrolase i immobilized on silica. j chromatogr 1993, 648, 2, 333.
Reference 8:
    niederreiter, k.s.; maier, n.m.; spitaler, m.m.; uray, g.; diphenylethanediamine derivatives as chiral selectors. viii. influence of the second amido function on the high-performance liquid chromatographic enantioseparation characteristics of (n-3,5-dinitrobenzoyl)-diphenylethanediamine based chiral stationary ph. j chromatogr 1998, 799, 1-2, 67.
Reference 9:
    uray, g.; kleidernigg, o.p.; maier, n.m.; lindner, w.; diphenylethanediamine (dpeda) derivatives as chiral selectors: iv. a comparison of 3,5-dinitrobenzoylated (s,s)- and (s,r)-dpeda-derived chiral stationary phases with pirkles standard (r)-phenylglycine-derived phase in normal phase hplc. chirality 1994, 6, 2, 116.
Reference 10:
    junggren, u.k.; sj?strand, s.e. (h?ssle l?kemedel ab); substd. pyridylsulfinylbenzimidazoles having gastric acid secretion properties, pharmaceutical preparations containing same, and intermediates for their preparation. ca 1129417; ep 0005129; us 4255431 .
Reference 11:
    lindberg, p.l.; von unge, s. (astrazeneca plc); optically pure salts of pyridinylmethyl sulfinyl-1h-benzimidazole cpds.. ep 1020460; ep 1020461; us 5693818; us 5714504; wo 9427988 .
Reference 12:
    taylor, s.; holt, r.; graham, d.; lindberg, p. (astrazeneca plc); enantioselective preparation of pharmaceutically active sulfoxides by bioreduction. wo 9617077 .
Reference 13:
    mattson, a.; hogberg, j.-a.; ioannidis, p. (astrazeneca plc); process for the preparation of a magnesium salt of a substd. sulphinyl heterocycle. jp 2000509067; wo 9741114 .
Reference 14:
    von unge, s. (astrazeneca plc); a process for the optical purification of enantiomerically enriched benzimidazole derivs.. wo 9702261 .
Reference 15:
    holt, r.; lindberg, p.; taylor, s.; reeve, c. (astrazeneca plc); enantioselective preparation of pharmaceutically active sulfoxides by biooxidation. wo 9617076 .
Reference 16:
    bergstrand, p.j.a.; lovgren, k.i. (astrazeneca plc); multiple unit tableted dosage form i. wo 9601623 .
Reference 17:
    von unge, p.o.s.; larsson, e.m.; cotton, h.k.; sorensen, h.; stenhede, u.j. (astrazeneca plc); process for synthesis of substd. sulphoxides. wo 9602535 .

Route 2
4) the reaction of racemic omeprazole (vii) with formaldehyde in dichloromethane gives, after crystallization in acetonitrile, 1-(hydroxymethyl)-6-methoxy-2-(4-methoxy-3,5-dimethyl-2-pyridinylmethylsulfinyl)-1h-benzimidazole (viii), which is treated with socl2 in dichloromethane to afford, after crystallization in acetonitrile, the corresponding chloromethyl derivative (ix). the condensation of (ix) with (r)-2-hydroxy-2-phenylacetic acid (x) by means of naoh and tetrabutylammonium hydrogen sulfate in water gives the corresponding ester (xi) as a diastereomeric mixture, which is resolved by reverse phase chromatography. finally, the suitable isomer is hydrolyzed to esomeprazole by treatment with naoh in methanol. (scheme 27259802a)esomeprazole magnesium can be obtained by three different ways: i) by reaction of esomeprazole with magnesium sulfate heptahydrate in aqueous ammonia; ii) by reaction of esomeprazole with magnesium methoxide in methanol or iii) by reaction of esomeprazole sodium, obtained by treatment of esomeprazole with naoh in 2-butanone, with hydrated magnesium chloride in water. (schemes 27259801a and 27259802a)
List of intermediates No.
4-[(5-chloro-2-nitrophenyl)sulfanyl]-1-methylpiperidine; 5-chloro-2-nitrophenyl 1-methyl-4-piperidinyl sulfide (x)
(2s)-1-(1,3-dithian-2-yl)-4-penten-2-ol (vi)
(1s)-1-(1,3-dithian-2-ylmethyl)-3-butenyl methyl ether; 2-[(2s)-2-methoxy-4-pentenyl]-1,3-dithiane (xiii)
(4r,6s)-4-([[tert-butyl(diphenyl)silyl]oxy]methyl)-6-(iodomethyl)-1,3-dioxan-2-one (viii)
tert-butyl(diphenyl)silyl (1r)-2-[[tert-butyl(diphenyl)silyl]oxy]-1-[(2s)oxiranylmethyl]ethyl ether; (5r)-2,2,9,9-tetramethyl-5-[(2s)oxiranylmethyl]-3,3,8,8-tetraphenyl-4,7-dioxa-3,8-disiladecane (ix)
(2s,4r)-4,5-bis[[tert-butyl(diphenyl)silyl]oxy]-1-[2-[(2s)-2-methoxy-4-pentenyl]-1,3-dithian-2-yl]-2-pentanol (xi)
tert-butyl(diphenyl)silyl [(2r,4s,6r)-4-[[tert-butyl(diphenyl)silyl]oxy]-6-methoxy-6-[(2s)-2-methoxy-4-pentynyl]tetrahydro-2h-pyran-2-yl]methyl ether; tert-butyl([(2r,4s,6r)-4-[[tert-butyl(diphenyl)silyl]oxy]-6-methoxy-6-[(2s)-2-methoxy-4-pentynyl]tetrahydro-2h-pyran-2-yl]methoxy)diphenylsilane (xii)
Reference 1:
    casta?er, r.m.; casta?er, j.; graul, a.; esomeprazole magnesium. drugs fut 1999, 24, 11, 1178.
Reference 2:
    alminger, t.b.; bergman, r.a.; bundgaard, h.; lindberg, p.l.; sunden, g.e. (hassle lakemedel ab); benzimidazole derivs.. au 8783302; ep 0279149; ep 0332647; ep 0510719; jp 1990500744; us 5215974; wo 8803921 .
Reference 3:
    von unge, s. (astrazeneca plc); novel ethoxycarbonyloxymethyl derivs. of substd. benzimidazoles. wo 9532957 .
Reference 4:
    lindberg, p.l.; von unge, s. (astrazeneca plc); optically pure salts of pyridinylmethyl sulfinyl-1h-benzimidazole cpds.. ep 1020460; ep 1020461; us 5693818; us 5714504; wo 9427988 .
Reference 5:
    bergstrand, p.j.a.; lovgren, k.i. (astrazeneca plc); multiple unit tableted dosage form i. wo 9601623 .
Reference 6:
    mattson, a.; hogberg, j.-a.; ioannidis, p. (astrazeneca plc); process for the preparation of a magnesium salt of a substd. sulphinyl heterocycle. jp 2000509067; wo 9741114 .

来源:药化网

作者:药化小编

摘要:本文合成路线介绍的是药物中文名埃索美拉唑镁;英文名Perprazole;(-)-Omeprazole magnesium;(S)-Omeprazole magnesium;Esomeprazole magnesium;H-199/18;Nexium;CAS[161973-10-0]

 
推荐VIP企业
无锡景耀生物科技有限公司
杭州卢普生物科技有限公司
宁波赛伦化工有限公司
苏州昊赛生物科技有限公司
北京嘉盛扬医药科技有限公司
上海泽涵生物医药科技有限公司
河北固安三利化工公司
郑州凯普瑞生物技术有限公司
上海药谷药业有限公司
兰州康寓信生物科技有限公司
湖北朗昕生化药业有限公司
武汉福鑫化工有限公司
嘉兴市英南化工有限公司
苏州迪飞医药科技有限公司
北京富安凯科技有限公司
上海盛中医药化工有限公司
连云港天和化学有限公司
南京晨瑞医药科技有限公司
南京苏如化工有限公司
常州瑞盛化工有限公司
热门文章
呋虫胺和烯啶虫胺继续扩作
华东地区丁二烯市场盘整
华南地区环氧丙烷市场稳定
损失或超6千万!这家上市公司被
丰山集团正式挂牌,发行首日秒封
山东地区环氧丙烷市场稳定
华中地区甲苯行情暂稳
东北地区甲苯行情暂稳
苯胺跌势难改
醋酸市场供需平衡
丙炔氟草胺领军“其他PPO抑制
华北地区醋酸价格整体上调
吡丙醚和氟啶虫酰胺继续扩作
新型“超分子纳米囊”可减少农药
PTA 回调为主
红太阳子公司南京生化完成增资工
嘧菌胺获欧盟批准开展再评审,但
新增一家毒氟磷制剂登记企业
装置集中检修 丁酮强势上涨难持
山东地区辛醇市场行情
 友情链接
有机化学人才网  
首页 | 广告服务 | 建站服务 | 关于我们 | 联系我们 | 版权声明